ProKidney (NASDAQ:PROK) vs. Gossamer Bio (NASDAQ:GOSS) Critical Contrast

Gossamer Bio (NASDAQ:GOSS) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Gossamer Bio and ProKidney, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	3	4	0	2.22
ProKidney	1	1	1	1	2.50

Gossamer Bio presently has a consensus target price of $3.20, indicating a potential upside of 1,707.91%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 620.72%. Given Gossamer Bio’s higher possible upside, analysts plainly believe Gossamer Bio is more favorable than ProKidney.

Profitability

This table compares Gossamer Bio and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
ProKidney	-8,131.50%	N/A	-21.39%

Volatility and Risk

Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gossamer Bio and ProKidney”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47 million	0.86	-$170.37 million	($0.79)	-0.22
ProKidney	$889,000.00	565.73	-$68.99 million	($0.53)	-3.14

ProKidney has lower revenue, but higher earnings than Gossamer Bio. ProKidney is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.